Association between Covid-19 BNT162b2 vaccination or SARS-CoV-2 infection and immune mediated diseases in 5 million 5-to-19-year-olds in four Nordic countries

Competing Interest Statement

OEK reports participation in research projects funded by Novo Nordisk, LEO Pharma and Bristol-Myers Squibb, all regulator-mandated phase IV studies, all with funds paid to their institution (no personal fees) and with no relation to the work reported in this paper. HLG reports previous participation in research projects and clinical trials funded by Novo Nordisk, GSK, AstraZeneca, and Boehringer-Ingelheim, all related to diabetes and paid to her previous institution Oslo University Hospital (no personal fees). She has received a lecture fee from Sanofi-Aventis (2018). AH reports unrelated grants from Independent Research Fund Denmark, the Novo Nordisk Foundation and the Lundbeck Foundation. AH is a scientific board member of VAC4EU. TN has received funding from Sanofi unrelated to the submitted work. TN and HN are employed at the Finnish Institute for Health and Welfare which has received research funding from Sanofi, GlaxoSmithKline SA, and Pfizer, Inc. outside of the submitted work. RL reports participation in a research project funded by Sanofi-Aventis, a regulator mandated phase IV study, with funds paid to his institution (no personal fees) and with no relation to the work reported in this paper (2011). RL has received a lecture fee from Pfizer with no relation to the work reported in this paper (2016)

Funding Statement

The study was funded and supported from the European Medicines Agency (study number 50201, EU PAS Number EUPAS48979),

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Denmark: The Danish study was conducted using administrative register data, which according to Danish law does not require external ethics approval. Finland: The Finnish study is a part of vaccine surveillance work, which is one of the duties of the Finnish Institute for Health and Welfare (THL). For this work, the institute is obliged to utilize all available data, including register data, to investigate potential harmful effects of the vaccines. Consent to participate was not applicable as this is a register-based study. Norway: The Norwegian study was approved by the Norwegian Regional Committee for Health Research Ethics South-East (REK Soer-OEst A, ref 122745). The emergency preparedness register BeredtC19 which provided data was established according to the Health Preparedness Act paragraph 2-4. Consent to participate was not applicable as this is a register-based study. Sweden: The Swedish study is approved by the Swedish Ethical Review Authority (2020-06859, 2021-02186). Consent to participate is not applicable as this is a register-based study. The study has only used de-identified data, which was not identifiable, and was not "re-identified" at any time during the study. For data protection, each participating country had access to their own data only.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes